v3.26.1
Consolidated Statements of Cash Flows - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Dec. 31, 2024
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Cash flows from operating activities:                    
Net loss $ (1,036,000) $ (1,172,000) $ (1,549,000) $ (1,808,000)   $ (2,208,000) $ (3,357,000) $ (5,162,000) [1] $ (9,559,000) [1] $ (14,121,000) [1]
Adjustments to reconcile net loss to net cash provided by operating activities:                    
Depreciation and amortization               106,000  
Amortization of operating lease right-of-use asset               329,000  
Stock-based compensation expense 2,000   6,000     5,000 14,000 25,000 511,000  
Loss on issuance of Series A offering securities               2,618,000  
Change in fair value of preferred stock forward liability   (1,000)     (67,000) (67,000) 67,000  
Changes in operating assets and liabilities:                    
Accounts receivable               928,000  
Prepaid expenses and other current assets           (330,000) 82,000 358,000 343,000  
Other long-term assets           13,000 13,000 163,000  
Accounts payable           257,000 (425,000) (537,000) (1,106,000)  
Accrued expenses           103,000 44,000 (63,000) (438,000)  
Lease liability               (333,000)  
Deferred revenue               (4,345,000)  
Net cash used by operating activities           (2,173,000) (3,696,000) (5,433,000) (10,716,000)  
Cash flows from investing activities:                    
Purchases of property and equipment               (398,000)  
Net cash provided by investing activities               (398,000)  
Cash flows from financing activities:                    
Proceeds from sale of Series B Convertible Preferred Stock           1,000,000      
Series B Convertible Preferred Stock issuance costs           (50,000)      
Net cash provided by financing activities           950,000      
Net increase in cash and cash equivalents:           (1,223,000) (3,696,000) (5,433,000) (11,114,000)  
Cash and cash equivalents at beginning of period   4,098,000   9,531,000   4,098,000 9,531,000 9,531,000 20,645,000  
Cash and cash equivalents at end of period 2,875,000   5,835,000   $ 9,531,000 2,875,000 5,835,000 4,098,000 9,531,000 $ 20,645,000
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:                    
Cash and cash equivalents 2,168,000   5,825,000   9,521,000 2,168,000 5,825,000 4,088,000 9,521,000  
Restricted cash 700,000       700,000    
Long-term restricted cash 7,000   10,000   10,000 7,000 10,000 10,000 10,000  
Supplemental disclosure of non-cash investing and financing activities                    
Right of use assets obtained in exchange for operating lease liability               8,423,000  
Accrued dividends on Series B Convertible Preferred Stock           16,000      
Eos SENOLYTIXS Inc [Member]                    
Cash flows from operating activities:                    
Net loss (2,997,289) (582,432) (57,461) (78,761) (76,895) (3,579,721) (136,222) (253,020)    
Adjustments to reconcile net loss to net cash provided by operating activities:                    
Parent-paid expenses treated as capital contribution         76,885 432,148 136,050 234,675    
Stock-based compensation expense         10 40,303 172 345    
Loss on issuance of Series A offering securities           556,000      
Change in fair value of preferred stock forward liability           (4,000)      
Amortization of deferred financing costs           125,153      
Amortization of debt discounts           13,409      
Issuance costs related to the Series A offering securities 80,464       80,464      
Non-cash financing expense related to Equity Incentive Shares           722,222        
Changes in operating assets and liabilities:                    
Prepaid expenses           (264,098)      
Right-of-use asset           86,107      
Accrued expenses         373,516 18,000    
Lease liability           (85,818)      
Interest payable           36,384        
Net cash used by operating activities         (1,467,931)    
Cash flows from investing activities:                    
Net cash provided by investing activities            
Cash flows from financing activities:                    
Payments of merger transaction costs           (377,159)        
Payments of deferred offering costs           (30,154)        
Proceeds from issuance of convertible notes payable           2,500,000        
Proceeds from issuance of Series A Preferred Stock           150,000      
Proceeds from preferred stock subscription           100,000        
Proceeds from short-term borrowings           100,000        
Net cash provided by financing activities         2,442,687    
Net increase in cash and cash equivalents:         974,756      
Cash and cash equivalents at beginning of period        
Cash and cash equivalents at end of period 974,756     974,756  
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:                    
Cash and cash equivalents $ 974,756       974,756    
Supplemental disclosure of cash flow information:                    
Interest paid            
Income taxes paid            
Cash paid for amounts included in the measurement of lease liabilities           94,050      
Supplemental disclosure of non-cash investing and financing activities                    
Right of use assets obtained in exchange for operating lease liability           389,076      
Debt discount and deferred financing costs related to noncash equity incentive share obligation           $ 277,778      
[1] The dollar amounts reported represent the amount of net loss, in thousands, reflected in Pulmatrix’s consolidated audited financial statements for each applicable year.